Rapid Onset of Response in Adults with Dermatomyositis Receiving Dazukibart: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study.

Numerical differences in mean CFB physical component score were observed as early as Week 4 ( Table 1 ), but the placebo-adjusted difference did not reach statistical significance with dazukibart 150 mg (−1.3 [−5.2, 2.7]; p=0.2996) or 600 mg (1.0 [−2.5, 4.4]; p=0.3205) ( Supplementary Figure S1 ).

also in 111,027 other papers